According to GlobalData’s medical device pipeline database, 2898 Immuno Chemistry devices are in various stages of development globally. GlobalData’s report Immuno Chemistry provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 1212 are in active development, while the remaining 1691 are in an inactive stage of development. There are 677 products in the early stages of development, and the remaining 535 are in the late stages of development.

Immuno Chemistry category includes reagents, instruments and test kits used for the analysis of antigen-antibody interactions in the body fluids. The category includes both test kits and reagents for quantification and detection of specific proteins, hormones, drug moieties and non-infectious diseases. Reagents and kits used in the diagnosis of infectious diseases are not included in this category.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Immuno Chemistry pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Immuno Chemistry devices. Overall, most of these Immuno Chemistry pipeline devices are being developed by private entities.

Key players involved in the active development of Immuno Chemistry include Roche Diagnostics International, Siemens Healthcare Diagnostics, Beckman Coulter, Johns Hopkins University, SomaLogic, Roche Diagnostics, Boditech Med, Group K Diagnostics, Guangzhou Wondfo Biotech and Quanterix.

For a complete picture of the developmental pipeline for Immuno Chemistry devices, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.